Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Research & Development (2023 - 2024)

Sagimet Biosciences has reported Research & Development over the past 2 years, most recently at $14.2 million for Q4 2024.

  • Quarterly results put Research & Development at $14.2 million for Q4 2024, up 151.34% from a year ago — trailing twelve months through Dec 2024 was $38.4 million (up 94.39% YoY), and the annual figure for FY2025 was $39.1 million, up 1.59%.
  • Research & Development for Q4 2024 was $14.2 million at Sagimet Biosciences, up from $12.7 million in the prior quarter.
  • Over the last five years, Research & Development for SGMT hit a ceiling of $14.2 million in Q4 2024 and a floor of $4.5 million in Q1 2023.